ATE333901T1 - Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin - Google Patents

Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin

Info

Publication number
ATE333901T1
ATE333901T1 AT01990621T AT01990621T ATE333901T1 AT E333901 T1 ATE333901 T1 AT E333901T1 AT 01990621 T AT01990621 T AT 01990621T AT 01990621 T AT01990621 T AT 01990621T AT E333901 T1 ATE333901 T1 AT E333901T1
Authority
AT
Austria
Prior art keywords
biguanine
metformin
arginine
pharmaceutical composition
diabetes
Prior art date
Application number
AT01990621T
Other languages
English (en)
Inventor
Jean-Robert Rapin
Dominique Halbitte
Original Assignee
Dospharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dospharma filed Critical Dospharma
Application granted granted Critical
Publication of ATE333901T1 publication Critical patent/ATE333901T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01990621T 2000-12-29 2001-12-31 Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin ATE333901T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0017332A FR2818906B1 (fr) 2000-12-29 2000-12-29 Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine

Publications (1)

Publication Number Publication Date
ATE333901T1 true ATE333901T1 (de) 2006-08-15

Family

ID=8858430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01990621T ATE333901T1 (de) 2000-12-29 2001-12-31 Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin

Country Status (15)

Country Link
US (2) US7265156B2 (de)
EP (1) EP1349578B1 (de)
JP (1) JP4477301B2 (de)
AT (1) ATE333901T1 (de)
CA (1) CA2435484A1 (de)
CY (1) CY1105736T1 (de)
DE (1) DE60121804T2 (de)
DK (1) DK1349578T3 (de)
ES (1) ES2271103T3 (de)
FR (1) FR2818906B1 (de)
NZ (1) NZ527206A (de)
PT (1) PT1349578E (de)
RU (1) RU2003123491A (de)
WO (1) WO2002053090A2 (de)
ZA (1) ZA200207761B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ598170A (en) 2009-10-02 2014-06-27 Boehringer Ingelheim Int Pharmaceutical compositions comprising bi-1356 and metformin
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sirs及び/又は敗血症の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
CN105277705A (zh) * 2014-07-24 2016-01-27 江苏维赛科技生物发展有限公司 一种检测双胍类药物残留的试剂盒的制备及其检测方法
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2037002A1 (en) 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
FR2696740B1 (fr) * 1992-10-13 1994-12-30 Dospharma Sa Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
AU738804B2 (en) * 1997-12-08 2001-09-27 Bristol-Myers Squibb Company Novel salts of metformin and method
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6517870B1 (en) * 1998-04-29 2003-02-11 Sumitomo Pharmaceuticals Company, Limited Oral formulation comprising biguanide and an organic acid
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
AU2001213150A1 (en) 2000-08-03 2002-02-18 Olga Evgenievna Kolesova Composition of metformin with succinic acid or salts thereof and method for treating diabetes

Also Published As

Publication number Publication date
EP1349578B1 (de) 2006-07-26
FR2818906A1 (fr) 2002-07-05
WO2002053090A3 (fr) 2003-02-20
DE60121804D1 (de) 2006-09-07
JP4477301B2 (ja) 2010-06-09
DK1349578T3 (da) 2006-11-27
CY1105736T1 (el) 2010-12-22
PT1349578E (pt) 2006-12-29
US20040097399A1 (en) 2004-05-20
FR2818906B1 (fr) 2004-04-02
NZ527206A (en) 2006-12-22
US20070265349A1 (en) 2007-11-15
US7265156B2 (en) 2007-09-04
ZA200207761B (en) 2004-05-28
EP1349578A2 (de) 2003-10-08
CA2435484A1 (fr) 2002-07-11
WO2002053090A2 (fr) 2002-07-11
ES2271103T3 (es) 2007-04-16
RU2003123491A (ru) 2005-01-10
DE60121804T2 (de) 2007-08-23
JP2004517105A (ja) 2004-06-10

Similar Documents

Publication Publication Date Title
DE60121804D1 (de) Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
SE0001899D0 (sv) New compounds
SE0002102D0 (sv) Chemical compound
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
CY1111543T1 (el) Νεες ενωσεις
SE9904505D0 (sv) Novel compounds
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
EA200400432A1 (ru) Производные мочевины
MX2007006397A (es) Derivados de tetrahidropirano.
SE0100901D0 (sv) New composition
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
SE0102438D0 (sv) New compounds
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
DE50202504D1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
IL159993A0 (en) Platinum complexes and their use in cancer treatment
MY134026A (en) ?-carboline derivatives and its pharmaceutical use against depression and anxiety
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
SE0102057D0 (sv) New Salts I
SE0101978D0 (sv) New compounds
ATE284703T1 (de) Kristallmodifikation eines cyclischen depsipeptids mit besserer wirksamkeit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1349578

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee